Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology

Background Early inclusion of Japan in the global development program could be a key factor in reducing the drug lag, making participation in phase I multiregional clinical trials (Ph. I MRCTs) an important consideration for oncology drug development in Japan. We aimed to investigate the factors ass...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic innovation & regulatory science 2024-07, Vol.58 (4), p.766-772
Main Authors: Maki, Akio, Narukawa, Mamoru
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Clinical trials
Clinical Trials, Phase I as Topic
Design factors
Drug Development
Drug Industry
Drug Safety and Pharmacovigilance
Humans
Japan
Medical Oncology
Medicine
Multicenter Studies as Topic
Neoplasms - drug therapy
Oncology
Original Research
Pharmaceutical industry
Pharmaceuticals
Pharmacotherapy
Pharmacy
Research Design
Subsidiaries
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Early inclusion of Japan in the global development program could be a key factor in reducing the drug lag, making participation in phase I multiregional clinical trials (Ph. I MRCTs) an important consideration for oncology drug development in Japan. We aimed to investigate the factors associated with the inclusion of Japan in Ph. I MRCTs in oncology. Methods We compared the trial design, target population, type of primary tested drug, trial conduct profile, and sponsor profile for Ph. I MRCTs with or without Japan conducted by the top 20 companies in more than two countries and started between January 1, 2011, and December 31, 2020. Results One hundred and ninety-seven Ph. I MRCTs included Japan, and 697 did not. Detailed features of the Ph. I MRCTs in oncology were summarized, and several factors (trial design, target population, trial conduct profile, and sponsor profile) associated with inclusion of Japan in the Ph. I MRCTs were identified. Conclusions It is important for Japanese subsidiaries within global pharmaceutical companies to closely communicate with the headquarters based on medical practice and unmet needs in Japan to join global development from an early stage. In addition, further efforts to attract emerging biopharmaceutical companies to Japan from the regulatory and/or political perspectives would be needed, thereby preventing drug lag in Japan.
ISSN:2168-4790
2168-4804
2168-4804
DOI:10.1007/s43441-024-00655-0